title: The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis.
abstract: The inclusion of a psychosis risk syndrome has been proposed for the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders. The appropriateness of inclusion of this new risk syndrome in the DSM depends on a careful analysis of both anticipated benefits and risks. Purported benefits include early recognition and case identification, and the hypothetical benefit of preventive intervention of psychotic disorders, for which there is as yet no clear evidence base. However, there is a potential for high rates of false positives particularly at the community level given the difficulty in discriminating mild symptoms from normal variants and low base rates of the syndrome in the general population. High false-positive rates in and of themselves are not necessarily problematic if the risk-benefit ratio is significantly favorable, as with screening for cardiovascular risk factors. For the psychosis risk syndrome, by contrast, there are substantial risks, for both stigma and discrimination, and for unnecessary exposure to antipsychotic medications, which make the high false-positive rate associated with the psychosis risk designation particularly problematic. More research is needed to improve the positive predictive value of the psychosis risk syndrome so that it can be considered for inclusion in future editions of the DSM.
authors.affiliation: Department of Psychiatry, New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Cc788@columbia.edu
authors.forename: Cheryl M
authors.initials: CM
authors.lastname: Corcoran
authors.forename: Michael B
authors.initials: MB
authors.lastname: First
authors.forename: Barbara
authors.initials: B
authors.lastname: Cornblatt
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects; D039721:Diagnostic and Statistical Manual of Mental Disorders; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis* / Q000188:drug therapy; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D014150:Antipsychotic Agents
references.citation: Arch Gen Psychiatry. 2001 Jul;58(7):663-8
references.pmid: 11448373
references.citation: Schizophr Bull. 2003;29(4):703-15
references.pmid: 14989408
references.citation: J Clin Psychiatry. 2007 Apr;68(4):546-57
references.pmid: 17474810
references.citation: Schizophr Res. 2003 Mar 1;60(1):21-32
references.pmid: 12505135
references.citation: Arch Gen Psychiatry. 2010 Feb;67(2):146-54
references.pmid: 20124114
references.citation: Schizophr Bull. 2007 May;33(3):665-72
references.pmid: 17255119
references.citation: Schizophr Bull. 2007 May;33(3):673-81
references.pmid: 17404389
references.citation: Schizophr Bull. 1998;24(1):99-113
references.pmid: 9502549
references.citation: Early Interv Psychiatry. 2009 May;3(2):108-15
references.pmid: 19777087
references.citation: Arch Gen Psychiatry. 2002 Oct;59(10):921-8
references.pmid: 12365879
references.citation: Am J Psychiatry. 2005 Jan;162(1):71-8
references.pmid: 15625204
references.citation: Can J Psychiatry. 1999 May;44(4):335-49
references.pmid: 10332574
references.citation: Schizophr Res. 2005 Mar 1;73(2-3):173-84
references.pmid: 15653260
references.citation: BMJ. 1994 Sep 17;309(6956):699-703
references.pmid: 7950522
references.citation: Circulation. 1998 May 12;97(18):1837-47
references.pmid: 9603539
references.citation: Arch Gen Psychiatry. 2008 Jan;65(1):28-37
references.pmid: 18180426
references.citation: Arch Gen Psychiatry. 2009 Sep;66(9):938-46
references.pmid: 19736350
references.citation: Schizophr Res. 2002 Mar 1;54(1-2):59-65
references.pmid: 11853979
references.citation: Biol Psychiatry. 2007 Feb 15;61(4):551-3
references.pmid: 16920077
references.citation: Br J Psychiatry Suppl. 2007 Dec;51:s96-101
references.pmid: 18055946
references.citation: Arch Gen Psychiatry. 2000 Nov;57(11):1053-8
references.pmid: 11074871
references.citation: Schizophr Res. 2008 Oct;105(1-3):10-7
references.pmid: 18765167
references.citation: Schizophr Bull. 2009 Sep;35(5):894-908
references.pmid: 19386578
references.citation: Am J Psychiatry. 1989 Jul;146(7):892-7
references.pmid: 2742015
references.citation: Aust N Z J Psychiatry. 2009 Feb;43(2):118-28
references.pmid: 19153919
references.citation: Br J Psychiatry Suppl. 1998;172(33):7-13
references.pmid: 9764120
references.citation: Am J Psychiatry. 2006 May;163(5):790-9
references.pmid: 16648318
references.citation: Arch Gen Psychiatry. 1992 Mar;49(3):221-35
references.pmid: 1373598
references.citation: Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
references.pmid: 16343296
references.citation: Biol Psychiatry. 2006 May 1;59(9):863-71
references.pmid: 16325151
references.citation: Br J Psychiatry. 2004 Oct;185:291-7
references.pmid: 15458988
references.citation: Schizophr Bull. 2003;29(4):633-51
references.pmid: 14989404
references.citation: Lancet. 1994 Nov 19;344(8934):1398-402
references.pmid: 7968076
references.citation: Harv Rev Psychiatry. 1996 Jan-Feb;3(5):293-5
references.pmid: 9384960